Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors

Specific anti-coronaviral drugs complementing available vaccines are urgently needed to fight the COVID-19 pandemic. Given its high conservation across the betacoronavirus genus and dissimilarity to human proteases, the SARS-CoV-2 main protease (Mpro) is an attractive drug target. SARS-CoV-2 Mpro inhibitors have been developed at unprecedented speed, most of them being substrate-derived peptidomimetics with cysteinemodifying warheads. In this study, Mpro has proven resistant towards the identification of high-affinity short substrate-derived peptides and peptidomimetics without warheads. 20 cyclic and linear substrate analogues bearing natural and unnatural residues, which were predicted by computational modelling to bind with high affinity and designed to establish structure-activity relationships, displayed no inhibitory activity at concentrations as high as 100 mu M. Only a long linear peptide covering residues P6 to P5 ' displayed moderate inhibition (Ki = 57 mu M). Our detailed findings will inform current and future drug discovery campaigns targeting Mpro.

Automated summary

This study highlights the challenges in identifying high-affinity short substrate-derived peptides and peptidomimetics without warheads for SARS-CoV-2 Mpro inhibition. Despite the development of inhibitors, only a long linear peptide displayed moderate inhibition, suggesting the need for further research in drug discovery targeting Mpro.